loading
Dechra Pharmaceuticals PLC Annual Report & Accounts for period ended 30 June 2013
Cookies This website uses cookies. Read our cookie policy for further details.
Developing
Focusing
Delivering
the Business through Investment in our Pipeline
Find out more >
on our Veterinary Pharmaceuticals Product Strategy
Sustainable Growth and Value
£ million
up 52.2%
up 53.1%
up 53.7%
pence
up 37.1%
up14.1%
up 78.5%
up 104.2%
up 31.6%
Watch the video >
Our European Pharmaceuticals Segment continues to show progress and achieved sales of £168.7 million, an increase of 66.3%.
The sale of the Services business is a significant step forward in achieving our clearly defined strategic objective.
Our divestment of the Services Segment (announced on 10 July 2013) was a logical strategic step following the successful acquisition of Eurovet